Coloplast A/S (OTCMKTS:CLPBY) Short Interest Down 42.6% in February

Coloplast A/S (OTCMKTS:CLPBY) was the recipient of a significant decrease in short interest in February. As of February 15th, there was short interest totalling 60,700 shares, a decrease of 42.6% from the January 31st total of 105,800 shares. Based on an average daily trading volume, of 242,400 shares, the short-interest ratio is currently 0.3 days.

Analyst Ratings Changes

Several brokerages recently weighed in on CLPBY. Hsbc Global Res raised shares of Coloplast A/S from a “moderate sell” rating to a “hold” rating in a research report on Monday, November 18th. Sanford C. Bernstein upgraded Coloplast A/S from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 28th. Finally, UBS Group upgraded Coloplast A/S from a “strong sell” rating to a “hold” rating in a report on Wednesday, December 11th.

Coloplast A/S Stock Down 1.3 %

Coloplast A/S stock traded down $0.14 during midday trading on Friday, reaching $10.60. 172,314 shares of the company traded hands, compared to its average volume of 189,949. Coloplast A/S has a 12 month low of $10.54 and a 12 month high of $14.34. The company has a quick ratio of 0.66, a current ratio of 1.02 and a debt-to-equity ratio of 0.92. The business has a 50 day moving average of $11.11 and a two-hundred day moving average of $12.32.

Coloplast A/S (OTCMKTS:CLPBY) last posted its quarterly earnings data on Tuesday, February 4th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.01). Coloplast A/S had a net margin of 17.81% and a return on equity of 28.60%. Analysts anticipate that Coloplast A/S will post 0.31 earnings per share for the current year.

Coloplast A/S Company Profile

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments.